• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Mannkind executive chairman Alfred Mann steps down

Mannkind executive chairman Alfred Mann steps down

February 19, 2016
CenterWatch Staff

Alfred E. Mann has resigned as executive chairman and as a board member of MannKind, effective immediately. MannKind named Kent Kresa as chairman of the board and also named Mann as chairman emeritus of MannKind. Mann will continue to advise the company as an employee in a non-executive capacity. 

"Al founded this company in order to bring his unique flair for medical innovation to the biopharmaceutical space," said Matthew Pfeffer, chief executive officer of MannKind. "We are awed by his many accomplishments during a legendary career and are proud to continue Al's decades-long pursuit of addressing the unmet needs of patients with diabetes and other serious illnesses."

"Al is a true visionary and has created a great company with an impressive lead product and powerful technology to help patients with serious diseases," said Kent Kresa, chairman of MannKind. "We have much to do to make his dreams a reality, but we have the people, technology and know-how to make that happen."

Kresa has been a director of MannKind since June 2004 and was named lead director in November 2011. Kresa is chairman emeritus of Northrop Grumman, having previously served as its chairman and chief executive officer. Kresa also served on the boards of General Motors, Avery Dennison (including as chairman) and Fluor. Kresa has been a member of the Caltech Board of Trustees since 1994, and he also serves on the boards of several nonprofit organizations and universities.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing